{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-016148","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.718756+00:00","generated_at":"2026-06-14T11:43:48.473954+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Director Mitchell Levinson leaves Pulse Biosciences board; continues as CSO","bullets":["Mitchell E. Levinson did not stand for reelection at the 2023 annual meeting, no disagreement cited.","All six director nominees elected; votes ranged from 22.3M to 23.3M for, with under 1M against per nominee.","Ratification of Deloitte & Touche as auditor passed with ~31.95M for, ~31K against.","Annual meeting held virtually on May 25, 2023; results filed in 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-016148","json":"https://secwatch.observer/filing/0001437749-23-016148.json","markdown":"https://secwatch.observer/filing/0001437749-23-016148.md","text":"https://secwatch.observer/filing/0001437749-23-016148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923016148/0001437749-23-016148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923016148/plse20230526_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:43:48.473954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"afeb469456","claim":"Mitchell E. Levinson departed as Director at PULSE BIOSCIENCES, INC..","evidence_excerpt":"Director Mitchell E. Levinson did not stand for reelection at the Annual Meeting, however he continues to serve as the Company’s Chief Strategy Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923016148/0001437749-23-016148-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"did not stand for reelection"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0fa7f4fef1cdd9d338221c6c05ba181f807541c6","claim":"PULSE BIOSCIENCES, INC. shareholders approved Election of six directors to hold office until the Company's 2024 annual meeting and until their successors are duly elected and qualified. at the 2023-05-25 meeting.","evidence_excerpt":"1. Election of Directors Nominee For Against Abstained Broker Non-votes Robert W. Duggan 22,304,832 1,000,283 239,290 8,561,105 Manmeet S. Soni 23,260,064 271,819 12,522 8,561,105 Shelley D. Spray 23,263,329 268,572 12,504 8,561,105 Darrin R. Uecker 23,239,193 271,552 33,660 8,561,105 Richard A. van den Broek 23,260,555 271,269 12,581 8,561,105 Mahkam Zanganeh, D.D.S. 23,259,164 272,463 12,778 8,561,105 Each director nominee was duly elected","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923016148/0001437749-23-016148-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"faf3abee25cf60edc155c6d50a00a7479844ef1f","claim":"PULSE BIOSCIENCES, INC. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.","evidence_excerpt":"2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 31,954,248 30,787 120,475 N/A The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774923016148/0001437749-23-016148-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}